Publications by authors named "Jonas Mandel"

Claim this Profile
C
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
Serguei Nabirotchkin, Jan Bouaziz, Fabrice Glibert, Jonas Mandel, Julie Foucquier

J Alzheimers Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.
Antonio J Vallejo-Vaz, Lawrence A Leiter, Stefano Del Prato, Marja-Riitta Taskinen, Dirk Müller-Wieland, Jonas Mandel

Eur J Prev Cardiol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Kausik K Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M Colhoun, Jonas Mandel

Cardiovasc Diabetol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Om P Ganda, Jorge Plutzky, Santosh K Sanganalmath, Maja Bujas-Bobanovic, Andrew Koren, Jonas Mandel

Diabetes Obes Metab· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Peter P Toth, Jamie P Dwyer, Christopher P Cannon, Helen M Colhoun, Daniel J Rader, Jonas Mandel

Kidney Int· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Peter A McCullough, Christie M Ballantyne, Santosh K Sanganalmath, Gisle Langslet, Seth J Baum, Jonas Mandel

Am J Cardiol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.
Philip D Harvey, Marwan N Sabbagh, John E Harrison, Henry N Ginsberg, M John Chapman, Jonas Mandel

Eur Heart J· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
Lawrence A Leiter, Bertrand Cariou, Dirk Müller-Wieland, Helen M Colhoun, Stefano Del Prato, Jonas Mandel

Diabetes Obes Metab· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-genome profiling helps to classify phyllodes tumours of the breast.
Marick Laé, Philippe La Rosa, Jonas Mandel, Fabien Reyal, Philippe Hupé

J Clin Pathol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Shahram Attarian, Jean-Michel Vallat, Laurent Magy, Benoît Funalot, Pierre-Marie Gonnaud, Jonas Mandel

Orphanet J Rare Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer's Disease.
Wenjia Wang, Jonas Mandel, Jan Bouaziz, Daniel Commenges, Serguei Nabirotchkine

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
Jonas Mandel, Viviane Bertrand, Philippe Lehert, Shahram Attarian, Laurent Magy

Orphanet J Rare Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Ilya Chumakov, Aude Milet, Nathalie Cholet, Gwenaël Primas, Aurélie Boucard, Jonas Mandel

Orphanet J Rare Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Shahram Attarian, Jean-Michel Vallat, Laurent Magy, Benoît Funalot, Pierre-Marie Gonnaud, Jonas Mandel

Orphanet J Rare Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMA - A R package for Easy Microarray data analysis.
Nicolas Servant, Eleonore Gravier, Pierre Gestraud, Cecile Laurent, Caroline Paccard, Jonas Mandel

BMC Res Notes· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics.
Lulla Opatowski, Jonas Mandel, Emmanuelle Varon, Pierre-Yves Boëlle, Laura Temime

Antimicrob Agents Chemother· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis